Arizona
Tuczon; Arizona Cancer Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Arkansas
Little Rock; University of Arkansas for Medical Sciences
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
California
Bakersfield; Comprehensive Blood and Cancer Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Bakersfield; Comprehensive Blood and Cancer Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Duarte; City of Hope
Randomized Pilot Trial of Oral Cyclophosphamide versus Oral Cyclophosphamide with Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Duarte; City of Hope
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
La Jolla; Rebecca & John Moores USCD Cancer Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Los Angeles; Cedars Sinai Medical Center - Women's Cancer Research Institute
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Newport Beach; Research Site![[*]](../images/newtiny.gif)
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
San Diego; Scripps Cancer Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Colorado
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Florida
New Port Rich; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Georgia
Athens; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Atlanta; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Savannah; Memorial Health University Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Savannah; Memorial Health University Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Savannah; Memorial Health University Medical Center
GOG-136: Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Illinois
Gurnee; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Indiana
Beech Grove; St. Francis Hospital and Health Centers
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Beech Grove; St. Francis Hospital and Health Centers
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)
South Bend; Northern Indiana Cancer Research Consortium
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
South Bend; Northern Indiana Cancer Research Consortium
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Kentucky
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Maryland
Baltimore; Greater Baltimore Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Baltimore; Greater Baltimore Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Massachusetts
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Minnesota
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Mississippi
Tupelo; Northern Mississippi Hematology/Oncology Associates
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Missouri
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Nebraska
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Nevada
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
New Hampshire
Lebanon; Dartmouth Hitchcock Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Lebanon; Dartmouth Hitchcock Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
New Jersey
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
New Mexico
Albuquerque; University of New Mexico Cancer Research and Treatment Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Albuquerque; University of New Mexico Cancer Research and Treatment
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
New York
Bronx; Biomedical Research Alliance of New York
Abnormal Pelvic Mass - Adults
Buffalo; Roswell Park Cancer Institute
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Jamaica; Biomedical Research Alliance of New York
Use of Neulasta with chemotherapy in elderly patients with cancer
New York; Mount Sinai Medical Center
A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Woman who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries [GOG0215]
New York; Mount Sinai Medical Center
A Phase II Evaluation of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338)) in Combination with Cisplatin (Commercially Available: NSC #119875) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma [GOG 0126-o]
New York; Mount Sinai Medical Center
An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma [GOG0190]
New York; Mount Sinai Medical Center
A Randomized Study of Tamoxifen Versus Thalidomide (NSC# 66847) in Patients with Biochemical-Recurrence-Only-Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy [GOG-0198]
New York; Mount Sinai Medical Center
Prospective Study of Risk-Reducing Salpingo-Ophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer [GOG 0199]
New York; Mount Sinai Medical Center
A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989, IND #70,252) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma [GOG-0170-G]
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
North Carolina
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Winston-Salem; Wake Forest University Health Sciences, Dept of Gynecological Oncology
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Ohio
Cleveland; MetroHealth Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Cleveland; MetroHealth Medical Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Oklahoma
Oklahoma City; University of Oklahoma Health Sciences Center
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Oklahoma City; University of Oklahoma Health Sciences Center - Department of Obstetrics and Gynecology
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Tulsa; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Oregon
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Pennsylvania
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Tennessee
Knoxville; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Knoxville; Hall and Martin, MD's, P.C.
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Texas
Amarillo; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Austin; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1In Patients With Adenocarcinoma Of The Stomach
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Ovary
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Uterine Cervix And/Or Vulva
San Antonio; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Utah
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Vermont
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Virginia
Charlottesville; University of Virginia
Women with Ovarian or Peritoneal Cancer Sought for Research Study.
Charlottesville; University of Virginia
Women who plan to have their ovaries removed sought for research study.
Roanoke; Carilion GYN Oncology Associates
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Roanoke; Carilion Healthcare Corporation dba Carilion GYNO
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Washington
Olympia; Research Site
Research Study of Carboplatin and DOXIL plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Tacoma; Henry M. Jackson Foundation - Madigan Army Medical Center - Hematology and Oncology
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Washington, DC
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
Wisconsin
Various Cities; Research Center
Ovarian Cancer Study CEPO906A2303
International
Bruxelles, Belgium; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Leuven, Belgium; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Wilrijk, Belgium; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Calgary, AB, Canada; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Edmonton, Canada; Cross Cancer Institute
National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
Kelowna, BC, Canada; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Vancouver, BC, Canada; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Budapest, Hungary; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Debrecen, Hungary; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Gyor, Hungary; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Milano, Italy; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Parma, Italy; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Amsterdam, Netherlands; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Poznan, Poland; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Warszawa, Poland; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Kazan, Russian Federation; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Moscow, Russian Federation; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
St Petersburg, Russian Federation; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Tomsk, Russian Federation; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Barcelona, Spain; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Madrid, Spain; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Valencia, Spain; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Birmingham, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
London, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Manchester, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Plymouth, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Sutton, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
Yeovil, United Kingdom; Research Site:
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
